TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

Researchers believe that engineering chimeric antigen receptor (CAR) T cells to recognize CD155 is a novel approach that could be appropriate for both hematologic and solid tumors.

Fludarabine is valued for its role in chimeric antigen receptor (CAR) T-cell therapy, but scientists believe moving away from fixed dosages could mediate better outcomes.

Research upholds the continued clinical value of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with Hodgkin lymphoma at a time when checkpoint inhibitors (CPIs) are...

Older adults preparing for allogeneic hematopoietic stem cell transplantation (allo-HSCT) may benefit from lower doses of fludarabine during reduced-intensity conditioning (RIC), researchers say.

Researchers present evidence, collected from several tumor models in mice, demonstrating the benefits of inhibition of interferon γ (IFN-γ) signaling in the setting of both hematologic and solid...

Chimeric antigen receptor (CAR) T-cell efficacy against solid tumors has room for improvement, and researchers are exploring low-dose radiation as one possible pathway to better outcomes.